Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patient-Focused Drug Development: Moving Up The Development Timeline

This article was originally published in RPM Report

Executive Summary

The patient-focused drug development effort initiated in PDUFA V has been flagged as a success by FDA and industry since it began, and the program is certain to be updated as part of PDUFA VI – if not early as part of the pending 21st Century Cures bill. The key objectives shared by stakeholders: broadening and systematizing patient input, and finding ways to bring it directly into the regulatory process.


Related Content

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta


Related Companies